20 March 2025
Nuformix plc
("Nuformix" or the "Company")
Result of Annual General Meeting
Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, announces that the Annual General Meeting ("AGM") of Nuformix plc was held earlier today and all resolutions put to shareholders were duly passed by a show of hands. The proxy votes received were as follows:
| | Resolution | Ordinary/Special | For |
| Against |
| Total votes cast |
|
| | | No. of votes | % | No. of votes | % | No. of votes |
| 1 | To receive the Company's annual report and accounts | Ordinary | 88,884,205 | 99.5 | 449,137 | 0.5 | 89,333,342 |
| 2 | To approve the Directors' Remuneration Policy | Ordinary | 87,134,389 | 98.05 | 1,732,136 | 1.95 | 88,866,525 |
| 3 | To approve the remuneration report | Ordinary | 87,134,389 | 98.07 | 1,712,636 | 1.93 | 88,847,025 |
| 4 | That Dr Daniel Gooding be re-appointed as a Director | Ordinary | 88,672,332 | 99.51 | 433,313 | 0.49 | 89,105,645 |
| 5 | That Dr Julian Gilbert be re-appointed as a Director | Ordinary | 88,632,832 | 99.49 | 453,313 | 0.51 | 89,086,145 |
| 6 | That Ms Madeleine Kennedy be re-appointed as a Director | Ordinary | 88,620,969 | 99.50 | 441,479 | 0.50 | 89,062,448 |
| 7 | To re-appoint Kreston Reeves LLP as auditor of the Company | Ordinary | 88,819,667 | 99.60 | 352,795 | 0.40 | 89,172,462 |
| 8 | To authorise the Directors to determine the auditor's remuneration | Ordinary | 87,612,217 | 98.51 | 1,321,125 | 1.49 | 88,933,342 |
| 9 | To authorise the Directors to allot securities | Ordinary | 84,636,256 | 94.81 | 4,630,269 | 5.19 | 89,266,525 |
| 10 | To authorise the Directors to disapply pre-emption rights | Special | 85,436,025 | 95.86 | 3,686,005 | 4.14 | 89,122,030 |
| 11 | To authorise the Company to purchase its own shares | Special | 87,796,808 | 98.88 | 992,039 | 1.12 | 88,788,847 |
| 12 | To authorise calling of a general meeting on 14 clear days' notice | Special | 88,600,047 | 99.18 | 733,295 | 0.82 | 89,333,342 |
A vote withheld is not a vote in law and is not counted in the calculation of votes validly cast for or against a resolution.
The Company's issued share capital is 1,669,309,368 ordinary shares of 0.05p each.
Enquiries:
| Nuformix plc Dr Daniel Gooding, Executive Director
| Via IFC Advisory |
| CMC Markets Douglas Crippen
| +44 (0) 20 3003 8632 |
| IFC Advisory Limited Tim Metcalfe Zach Cohen | +44 (0) 20 3934 6630 nuformix@investor-focus.co.uk |
About Nuformix
Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities. Nuformix has a pipeline of preclinical assets with potential for significant value and early licensing opportunities.
For more information, please visit www.nuformix.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
